Fibrates are an essential part of modern anti-dyslipidemic arsenal: spotlight on atherogenic dyslipidemia and residual risk reduction

Cardiovascular Diabetology

Volumn 11, Issue , 2012, Pages

  Tenenbaum, Alexander ^a,b,c   Fisman, Enrique Z ^b,c  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c Cardiovascular Diabetology Research Foundation   (Israel)

Author keywords

Atherogenic dyslipidemia; Bezafibrate; Combined fibrate statin therapy; Fenofibrate; Metabolic syndrome; Residual cardiovascular risk; Type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; CLOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR DELTA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLACEBO; TRIACYLGLYCEROL;

ATHEROGENESIS; ATHEROGENIC DYSLIPIDEMIA; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIABETIC RETINOPATHY; DISEASE SEVERITY; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; HEART INFARCTION; HUMAN; INTERMITTENT CLAUDICATION; KAPLAN MEIER METHOD; META ANALYSIS (TOPIC); METABOLIC SYNDROME X; MICROALBUMINURIA; MICROVASCULATURE; MONOTHERAPY; MORTALITY; MULTIVARIATE ANALYSIS; MYALGIA; MYOSITIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OBSERVATIONAL STUDY; PANCREAS ISLET BETA CELL; PHENOTYPE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK REDUCTION; TREATMENT OUTCOME;

ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FIBRIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPOLIPIDEMIC AGENTS; LIPIDS; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME;

EID: 84867235189     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-11-125     Document Type: Review

References (95)

1. Brown M, Byatt T, Marsh T, McPherson K. National heart forum: micro simulation of obesity trends 2006 - 2050: obesity trends for adults analysis from the health survey for England 1993 - 2007 February 2010 2010, National Heart Forum, London, http://nhfshare.heartforum.org.uk/RMAssets/NHFreports/NHF_adultobese_short_170210.pdf (Accessed October 1 2012).
2. National Diabetes Information Clearinghouse (NDIC) Diabetes overview. NIH publication No. 09-3873 2008, http://diabetes.niddk.nih.gov/dm/pubs/overview/ (Accessed October 1 2012), National Diabetes Information Clearinghouse (NDIC).
3. van Vliet M, Heymans MW, von Rosenstiel IA, Brandjes DP, Beijnen JH, Diamant M. Cardiometabolic risk variables in overweight and obese children: a worldwide comparison. Cardiovasc Diabetol 2011, 10:106. 10.1186/1475-2840-10-106, 3258193, 22114790.
4. Tenenbaum A, Motro M, Schwammenthal E, Fisman EZ. Macrovascular complications of metabolic syndrome: an early intervention is imperative. Int J Cardiol 2004, 97:167-172. 10.1016/j.ijcard.2003.07.033, 15458679.
5. Centers for Disease Control and Prevention National Diabetes Fact Sheet: National Estimates and General Information on Diabetes and Prediabetes in the United States, 2011 2011, U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta, Centers for Disease Control and Prevention.
6. Tenenbaum A, Fisman EZ. " The metabolic syndrome... is dead" : these reports are an exaggeration. Cardiovasc Diabetol 2011, 10:11. 10.1186/1475-2840-10-11, 3036609, 21269524.
7. Haffner SM, Lehto S, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234. 10.1056/NEJM199807233390404, 9673301.
8. Donahoe SM, Stewart GC, McCabe CH, Mohanavelu S, Murphy SA, Cannon CP, Antman EM. Diabetes and mortality following acute coronary syndromes. JAMA 2007, 298:765-775. 10.1001/jama.298.7.765, 17699010.
9. Reynoso-Noverón N, Mehta R, Almeda-Valdes P, Rojas-Martinez R, Villalpando S, Hernández-Ávila M, Aguilar-Salinas CA. Estimated incidence of cardiovascular complications related to type 2 diabetes in Mexico using the UKPDS outcome model and a population-based survey. Cardiovasc Diabetol 2011, 10:1. 10.1186/1475-2840-10-1, 3023678, 21214916.
10. Gami AS, Witt BJ, Howard DE, Erwin PJ, Gami LA, Somers VK, Montori VM. Metabolic syndrome and risk of incident cardiovascular events and death: a systematic review and meta-analysis of longitudinal studies. J Am Coll Cardiol 2007, 49:403-414. 10.1016/j.jacc.2006.09.032, 17258085.
11. Galassi A, Reynolds K, He J. Metabolic syndrome and risk of cardiovascular disease: a meta-analysis. Am J Med 2006, 119:812-819. 10.1016/j.amjmed.2006.02.031, 17000207.
12. Mottillo S, Filion KB, Genest J, Joseph L, Pilote L, Poirier P, Rinfret S, Schiffrin EL, Eisenberg MJ. The metabolic syndrome and cardiovascular risk. A systematic review and meta-analysis. J Am Coll Cardiol 2010, 56:1113-1132. 10.1016/j.jacc.2010.05.034, 20863953.
13. Scott R, Donoghoe M, Watts GF, O'Brien R, Pardy C, Taskinen MR, Davis TM, Colman PG, Manning P, Fulcher G, Keech AC, . FIELD Study Investigators Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial. Cardiovasc Diabetol 2011, 10:102. 10.1186/1475-2840-10-102, 3286386, 22104275, FIELD Study Investigators.
14. Ninomiya JK, L'Italien G, Criqui MH, Whyte JL, Gamst A, Chen RS. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004, 109:42-46. 10.1161/01.CIR.0000116602.10533.2E, 14676144.
15. Austin MA, Breslow JL, Hennekens CH, Buring JE, Willett WC, Krauss RM. Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA 1988, 260:1917-1921. 10.1001/jama.1988.03410130125037, 3418853.
16. Austin MA, King MC, Vranizan KM, Krauss RM. Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation 1990, 82:495-506. 10.1161/01.CIR.82.2.495, 2372896.
17. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421. .
18. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol 2006, 5:20. 10.1186/1475-2840-5-20, 1592077, 17002798.
19. Ghandehari H, Kamal-Bahl S, Wong ND. Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J 2008, 156:112-119. 10.1016/j.ahj.2008.03.005, 18585505.
20. Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention?. J Atheroscler Thromb 2005, 12:237-239. 10.5551/jat.12.237, 16205019.
21. Li C, Ford ES, Tsai J, Zhao G, Balluz LS, Gidding SS. Serum non-high-density lipoprotein cholesterol concentration and risk of death from cardiovascular diseases among U.S. adults with diagnosed diabetes: the Third National Health and Nutrition Examination Survey linked mortality study. Cardiovasc Diabetol 2011, 10:46. 10.1186/1475-2840-10-46, 3127754, 21605423.
22. Sarwar N, Sandhu MS, Ricketts SL, Butterworth AS, Di Angelantonio E, Boekholdt SM, Ouwehand W, Watkins H, Samani NJ, Saleheen D, Lawlor D, Reilly MP, Hingorani AD, Talmud PJ, Danesh J, . Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet 2010, 375:1634-1639. 2867029, 20452521, Triglyceride Coronary Disease Genetics Consortium and Emerging Risk Factors Collaboration.
23. Chaudhary R, Likidlilid A, Peerapatdit T, Tresukosol D, Srisuma S, Ratanamaneechat S, Sriratanasathavorn C. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol 2012, 11:36. 10.1186/1475-2840-11-36, 3372424, 22520940.
24. Chiang JK, Lai NS, Chang JK, Koo M. Predicting insulin resistance using the triglyceride-to-high-density lipoprotein cholesterol ratio in Taiwanese adults. Cardiovasc Diabetol 2011, 10:93. 10.1186/1475-2840-10-93, 3224454, 22004541.
25. Hopkins PN, Wu LL, Hunt SC, Brinton EA. Plasma triglycerides and type III hyperlipidemia are independently associated with premature familial coronary artery disease. J Am Coll Cardiol 2005, 45:1003-1012. 10.1016/j.jacc.2004.11.062, 15808755.
26. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S, Boekholdt SM, Khaw KT, Gudnason V. Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation 2007, 115:450-458. 10.1161/CIRCULATIONAHA.106.637793, 17190864.
27. Miller M, Stone NJ, Ballantyne C, Bittner V, Criqui MH, Ginsberg HN, Goldberg AC, Howard WJ, Jacobson MS, Kris-Etherton PM, Lennie TA, Levi M, Mazzone T, Pennathur S, . American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism Council on Arteriosclerosis, Thrombosis and Vascular Biology Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation 2011, 123:2292-2333. 10.1161/CIR.0b013e3182160726, 21502576, American Heart Association Clinical Lipidology, Thrombosis, and Prevention Committee of the Council on Nutrition, Physical Activity, and Metabolism Council on Arteriosclerosis, Thrombosis and Vascular Biology Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease.
28. Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A. Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA 2007, 298:299-308. 10.1001/jama.298.3.299, 17635890.
29. Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM. Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 2007, 298:309-316. 10.1001/jama.298.3.309, 17635891.
30. Mackey RH, Greenland P, Goff DC, Lloyd-Jones D, Sibley CT, Mora S. High-Density Lipoprotein Cholesterol and Particle Concentrations, Carotid Atherosclerosis, and Coronary Events: MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2012, 60:508-516. 10.1016/j.jacc.2012.03.060, 3411890, 22796256.
31. Goldenberg I, Boyko V, Tennenbaum A, Tanne D, Behar S, Guetta V. Long-term benefit of high-density lipoprotein cholesterol-raising therapy with bezafibrate: 16-year mortality follow-up of the bezafibrate infarction prevention trial. Arch Intern Med 2009, 169:508-514. 10.1001/archinternmed.2008.584, 19273782.
32. Manninen V, Elo MO, Frick MH, Haapa K, Heinonen OP, Heinsalmi P, Helo P, Huttunen JK, Kaitaniemi P, Koskinen P, Mäenpää H, Mälkönen M, Mänttäri M, Norola S, Pasternack A, Pikkarainen J, Romo M, Sjöblom T, Nikkilä ES. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988, 260:641-651. 10.1001/jama.1988.03410050061031, 3164788.
33. Hermans MP, Sacks FM, Ahn SA, Rousseau MF. Non-HDL-cholesterol as valid surrogate to apolipoprotein B100 measurement in diabetes: Discriminant Ratio and unbiased equivalence. Cardiovasc Diabetol 2011, 10:20. 10.1186/1475-2840-10-20, 3056766, 21356116.
34. Natarajan P, Ray KK, Cannon CP. High-density lipoprotein and coronary heart disease: current and future therapies. J Am Coll Cardiol 2010, 55:1283-1299. 10.1016/j.jacc.2010.01.008, 20338488.
35. Boden WE, Probstfield JL, Anderson T, Chaitman BR, Desvignes-Nickens P, Koprowicz K, McBride R, Teo K, Weintraub W, . AIM-HIGH Investigators Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011, 365:2255-2267. AIM-HIGH Investigators.
36. Rizos EC, Ntzani EE, Bika E, Kostapanos MS, Elisaf MS. Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 2012, 308:1024-1033. 10.1001/2012.jama.11374, 22968891.
37. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999, 341:498-511. 10.1056/NEJM199908123410707, 10441607.
38. Tenenbaum A, Fisman EZ, Motro M, Adler Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?. Adv Cardiol 2008, 45:127-153.
39. ACCORD Study Group Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010, 362:1563-1574. 2879499, 20228404, ACCORD Study Group.
40. Tenenbaum A, Fisman EZ. " If it ain't broke, don't fix it" : a commentary on the positive-negative results of the ACCORD Lipid study. Cardiovasc Diabetol 2010, 9:24. 10.1186/1475-2840-9-24, 2893121, 20550659.
41. Scott R, O'Brien R, Fulcher G, Pardy C, D'Emden M, Tse D, Taskinen MR, Ehnholm C, Keech A, . Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care 2009, 32:493-498. 10.2337/dc08-1543, 2646035, 18984774, Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study Investigators.
42. The BIP Study Group Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27. The BIP Study Group.
43. Manninen V, Tenkanen L, Koskinen P, Huttunen JK, Mänttäri M, Heinonen OP, Frick MH. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study: implications for treatment. Circulation 1992, 85:37-45. 10.1161/01.CIR.85.1.37, 1728471.
44. Robins SJ, Collins D, Wittes JT, Papademetriou V, Deedwania PC, Schaefer EJ, McNamara JR, Kashyap ML, Hershman JM, Wexler LF, Rubins HB, . VA-HIT Study Group Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial. JAMA 2001, 285:1585-1591. 10.1001/jama.285.12.1585, 11268266, VA-HIT Study Group.
45. Keech A, Simes RJ, Barter P, Best J, Scott R, Taskinen MR, Forder P, Pillai A, Davis T, Glasziou P, Drury P, Kesäniemi YA, Sullivan D, Hunt D, Colman P, d'Emden M, Whiting M, Ehnholm C, Laakso M, . FIELD study investigators Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet 2005, 366:1849-1861. FIELD study investigators.
46. Sacks FM, Carey VJ, Fruchart JC. Combination lipid therapy in type 2 diabetes. N Engl J Med 2010, 363:692-694.
47. Jun M, Foote C, Lv J, Neal B, Patel A, Nicholls SJ, Grobbee DE, Cass A, Chalmers J, Perkovic V. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis. Lancet 2010, 375:1875-1878. 10.1016/S0140-6736(10)60656-3, 20462635.
48. Meade T, Zuhrie R, Cook C, Cooper J. Bezafibrate in men with lower extremity arterial disease: randomised controlled trial. BMJ 2002, 325(7373):1139. 10.1136/bmj.325.7373.1139, 133451, 12433762.
49. Khazaei M, Salehi E, Rashidi B. Pan-PPAR agonist, bezafibrate, restores angiogenesis in hindlimb ischemia in normal and diabetic rats. Int J Pept 2012, 2012:637212. 3371757, 22701496.
50. Harrold BP, Marmion VJ, Gough KR. A double-blind controlled trial of clofibrate in the treatment of diabetic retinopathy. Diabetes 1969, 18:285-391.
51. Duncan LJ, Cullen JF, Ireland JT, Nolan J, Clarke BF, Oliver MF. A three-year trial of atromid therapy in exudative diabetic retinopathy. Diabetes 1968, 17:458-467.
52. Hermans MP. Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD. Diab Vasc Dis Res 2011, 8:180-189. 10.1177/1479164111407783, 21576195.
53. Kim J, Ahn JH, Kim JH, Yu YS, Kim HS, Ha J, Shinn SH, Oh YS. Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway. Exp Eye Res 2007, 84:886-893. 10.1016/j.exer.2007.01.009, 17343853.
54. Tenenbaum A, Motro M, Fisman EZ. Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. Cardiovasc Diabetol 2005, 4:14. 10.1186/1475-2840-4-14, 1236941, 16168052.
55. Willson TM, Brown PJ, Sternbach DD, Henke BR. The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550. 10.1021/jm990554g, 10691680.
56. Tenenbaum A, Fisman EZ, Boyko V, Benderly M, Tanne D, Haim M, Matas Z, Motro M, Behar S. Attenuation of progression of insulin resistance in patients with coronary artery disease by bezafibrate. Arch Intern Med 2006, 166:737-741. 10.1001/archinte.166.7.737, 16606809.
57. Ogawa S, Takeuchi K, Sugimura K, Fukuda M, Lee R, Ito S, Sato T. Bezafibrate reduces blood glucose in type 2 diabetes mellitus. Metabolism 2000, 49:331-334. 10.1016/S0026-0495(00)90176-8, 10726910.
58. Tenenbaum H, Behar S, Boyko V, Adler Y, Fisman EZ, Tanne D, Lapidot M, Schwammenthal E, Feinberg M, Matas Z, Motro M, Tenenbaum A. Long-term effect of bezafibrate on pancreatic beta-cell function and insulin resistance in patients with diabetes. Atherosclerosis 2007, 194:265-271. 10.1016/j.atherosclerosis.2006.08.005, 16970952.
59. Teramoto T, Shirai K, Daida H, Yamada N. Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study. Cardiovasc Diabetol 2012, 11:29. 10.1186/1475-2840-11-29, 3342914, 22439599.
60. Hiuge A, Tenenbaum A, Maeda N, Benderly M, Kumada M, Fisman EZ, Tanne D, Matas Z, Hibuse T, Fujita K, Nishizawa H, Adler Y, Motro M, Kihara S, Shimomura I, Behar S, Funahashi T. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 2007, 27:635-644. 10.1161/01.ATV.0000256469.06782.d5, 17194889.
61. Tenenbaum A, Motro M, Fisman EZ, Schwammenthal E, Adler Y, Goldenberg I, Leor J, Boyko V, Mandelzweig L, Behar S. Peroxisome proliferator-activated receptors ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109:2197-2202. 10.1161/01.CIR.0000126824.12785.B6, 15123532.
62. Tenenbaum A, Motro M, Fisman EZ, Adler Y, Shemesh J, Tanne D, Leor J, Boyko V, Schwammenthal E, Behar S. Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients. Eur Heart J 2005, 26:2032-2038. 10.1093/eurheartj/ehi310, 15872029.
63. Flory JH, Ellenberg S, Szapary PO, Strom BL, Hennessy S. Antidiabetic action of bezafibrate in a large observational database. Diabetes Care 2009, 32:547-551. 10.2337/dc08-1809, 2660490, 19131462.
64. Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for the secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch Intern Med 2005, 165:1154-1160. 10.1001/archinte.165.10.1154, 15911729.
65. Sano K, Nakamura T, Hirano M, Kitta Y, Kobayashi T, Fujioka D, Saito Y, Yano T, Watanabe K, Watanabe Y, Mishina H, Obata JE, Kawabata K, Kugiyama K. Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein. Circ J 2010, 74:1644-1650. 10.1253/circj.CJ-10-0079, 20574136.
66. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002, 360:7-22. Heart Protection Study Collaborative Group.
67. Sacks FM, Tonkin AM, Shepherd J, Braunwald E, Cobbe S, Hawkins CM, Keech A, Packard C, Simes J, Byington R, Furberg CD, . for the Prospective Pravastatin Pooling Project Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. Circulation 2000, 102:1893-1900. 10.1161/01.CIR.102.16.1893, 11034935, for the Prospective Pravastatin Pooling Project.
68. Ballantyne CM, Herd JA, Ferlic LL, Dunn JK, Farmer JA, Jones PH, Schein JR, Gotto AM. Influence of low HDL on progression of coronary artery disease and response to fluvastatin therapy. Circulation 1999, 99:736-743. 10.1161/01.CIR.99.6.736, 9989957.
69. Scandinavian Simvastatin Survival Study Group Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet 1995, 345:1274-1275. Scandinavian Simvastatin Survival Study Group.
70. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998, 339:1349-1357. The Long-Term Intervention With Pravastatin in Ischaemic Disease (LIPID) Study Group.
71. Pfeffer MA, Sacks FM, Moyé LA, East C, Goldman S, Nash DT, Rouleau JR, Rouleau JL, Sussex BA, Theroux P, Vanden Belt RJ, Braunwald E. Influence of baseline lipids on effectiveness of pravastatin in the CARE trial. J Am Coll Cardiol 1999, 33:125-130. 10.1016/S0735-1097(98)00522-1, 9935018.
72. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFarlane PW, McKillop JH, Packard CJ. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307. 10.1056/NEJM199511163332001, 7566020.
73. Downs JR, Clearfield M, Weis S, Whitney E, Shapiro DR, Beere PA, Langendorfer A, Stein EA, Kruyer W, Gotto AM. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 1998, 279:1615-1622. 10.1001/jama.279.20.1615, 9613910.
74. Chapman MJ, Redfern JS, McGovern ME, Giral P. Optimal pharmacotherapy to combat the atherogenic lipid triad. Curr Opin Cardiol 2011, 26:403-411. 10.1097/HCO.0b013e32834965e9, 21730827.
75. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators: intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504. 10.1056/NEJMoa040583, 15007110.
76. de Lemos JA, Blazing MA, Wiviott SD, Lewis EF, Fox KA, White HD, Rouleau JL, Pedersen TR, Gardner LH, Mukherjee R, Ramsey KE, Palmisano J, Bilheimer DW, Pfeffer MA, Califf RM, Braunwald E, . A to Z Investigators Early intensive vs. a delayed conservative simvastatin strategy in patients with acute coronary syndromes: phase Z of the A to Z trial. JAMA 2004, 292:1307-1316. 10.1001/jama.292.11.1307, 15337732, A to Z Investigators.
77. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Treating to New Targets (TNT) Investigators: intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005, 352:1425-1435. 10.1056/NEJMoa050461, 15755765.
78. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J, . Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA 2005, 294:2437-2445. 10.1001/jama.294.19.2437, 16287954, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group.
79. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R, . Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. Lancet 2010, 376:1658-1669. 10.1016/S0140-6736(10)60310-8, 2988223, 21067805, Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group.
80. Cannon CP, Steinberg BA, Murphy SA, Mega JL, Braunwald E. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. J Am Coll Cardiol 2006, 48:438-445. 10.1016/j.jacc.2006.04.070, 16875966.
81. Wagstaff LR, Mitton MW, Arvik BM, Doraiswamy PM. Statin-associated memory loss: analysis of 60 case reports and review of the literature. Pharmacotherapy 2003, 23:871-880. 10.1592/phco.23.7.871.32720, 12885101.
82. Muldoon MF, Ryan CM, Sereika SM, Flory JD, Manuck SB. Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults. Am J Med 2004, 117:823-829. 10.1016/j.amjmed.2004.07.041, 15589485.
83. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, Manson JE, Qiao Y, Liu S, Merriam PA, Rahilly-Tierny C, Thomas F, Berger JS, Ockene JK, Curb JD, Ma Y. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med 2012, 172:144-152. 10.1001/archinternmed.2011.625, 22231607.
84. Jones PH, Davidson MH. Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin. Am J Cardiol 2005, 95:120-122. 10.1016/j.amjcard.2004.08.076, 15619408.
85. Fruchart JC, Sacks F, Hermans MP, Assmann G, Brown WV, Ceska R, Chapman MJ, Dodson PM, Fioretto P, Ginsberg HN, Kadowaki T, Lablanche JM, Marx N, Plutzky J, Reiner Z, Rosenson RS, Staels B, Stock JK, Sy R, Wanner C, Zambon A, Zimmet P. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102:1K-34K. 10.1016/j.amjcard.2008.10.002, 19068318.
86. Farnier M. Combination Therapy with an HMG-CoA Reductase Inhibitor and a Fibric Acid Derivative: a Critical Review of Potential Benefits and Drawbacks. Am J Cardiovasc Drugs 2003, 3:169-178. 10.2165/00129784-200303030-00003, 14727929.
87. Shek A, Ferrill MJ. Statin-fibrate combination therapy. Ann Pharmacother 2001, 35:908-917.
88. Prueksaritanont T, Tang C, Qui Y, Mu L, Subramanian R, Lin JH. Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos 2002, 30:1280-1287. 10.1124/dmd.30.11.1280, 12386136.
89. Backman JT JT, Kyrklund C, Kivistö KT, Wang JS, Neuvonen PJ. Plasma concentrations of active simvastatin acid are increased by gemfibrozil. Clin Pharmacol Ther 2000, 68:122-129. 10.1067/mcp.2000.108507, 10976543.
90. Kyrklund C, Backman JT, Kivistö KT, Neuvonen M, Laitila J, Neuvonen PJ. Plasma conentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate. Clin Pharmacol Ther 2001, 69:340-345. 10.1067/mcp.2001.115542, 11372002.
91. Kehely A, MacMahon M, Barbir M, Wray R, Hunt BJ, Prescott RJ, Thompson GR. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia. QJM 1995, 88:421-427.
92. Gavish D, Leibovitz E, Shapira I, Rubinstein A. Bezafibrate and simvastatin combination therapy for diabetic dyslipidaemia: efficacy and safety. J Intern Med 2000, 247:563-569. 10.1046/j.1365-2796.2000.00646.x, 10809995.
93. Bergman AJ, Murphy G, Burke J, Zhao JJ, Valesky R, Liu L, Lasseter KC, He W, Prueksaritanont T, Qiu Y, Hartford A, Vega JM, Paolini JF. Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans. J Clin Pharmacol 2004, 44:1054-1062. 10.1177/0091270004268044, 15317833.
94. Madrid-Miller A, Moreno-Ruiz LA, Borrayo-Sánchez G, Almeida-Gutiérrez E, Martínez-Gómez DF, Jáuregui-Aguilar R. Impact of bezafibrate treatment in patients with hyperfibrinogenemia and ST-elevation acute myocardial infarction: a randomized clinical trial. Cir Cir 2010, 78:229-237.
95. Tenenbaum A, Medvedofsky D, Fisman EZ, Bubyr L, Matetzky S, Tanne D, Klempfner R, Shemesh J, Goldenberg I. Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data. PLoS One 2012, 7(4):e35298. 10.1371/journal.pone.0035298, 3327654, 22523582.